Data / Form D filings / Synchrony Medical Inc.
Synchrony Medical Inc.: Form D filings
Synchrony Medical Inc., a biotechnology company in Jersey City, NJ, filed 2 Form D notices with the SEC between 2025 and 2026. The latest, on March 10, 2026, reports $4.3 million sold of a $4.3 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 222 JERSEY CITY BLVD., Jersey City, NJ, 07305
- Phone
- (800) 590-1807
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2085429
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Amendment | $4,300,000 | $4,300,000 | 12 | Aug 19, 2025 | sec.gov | |
| Sep 12, 2025 | New notice | $2,500,000 | $1,000,000 | $1,500,000 | 7 | Aug 19, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Anat Shani | Executive Officer, Director | |
| Eileen Ke | Director | |
| Shai Policker | Director | |
| Kevin Kotler | Director | |
| Elad Dushack | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Mar 9, 2026 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Synchrony Medical Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.